Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Daman AW, Josefowicz SZ. Epigenetic and transcriptional control of interferon-β. J Exp Med. 2021;218(9).

Tong J, Luo J, Saldinger PF, Rodgers WH. A Rare Case of Histiocytic Sarcoma Secondary to Gastrointestinal Stromal Tumor in the Stomach: Transdifferentiation or Synchronicity? Case Rep Hematol. 2021;2021:8856649.

Patel A, Hissong E, Rosado L, Burkhardt R, Cong L, Alperstein SA, et al. Next-Generation Sequencing of Cell-Free DNA Extracted From Pleural Effusion Supernatant: Applications and Challenges. Front Med (Lausanne). 2021;8:662312.

Oh H, Hwang I, Jang J-, Wu L, Cao D, Yao J, et al. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling. Cancer Res. 2021;81(6):1528-1539.

Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. bioRxiv. 2021.

Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, et al. Tumor size and genomic risk in localized prostate cancer. Urol Oncol. 2021;39(7):434.e17-434.e22.

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clin Chem. 2021;67(9):1249-1258.

Romero-Velez G, Pereira X, Yang J, Panarelli NC, McAuliffe JC. Neuroendocrine Tumor of the Common Bile Duct Associated With von Hippel-Lindau Disease. ACG Case Rep J. 2021;8(2):e00512.

Tabbo F, Guerrera F, van den Berg A, Gaudiano M, Maletta F, Bessone L, et al. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. Eur J Cancer. 2021;144:17-30.